In May 2023, the US Department of Transportation (DOT) published its final rule permitting oral fluid drug testing for DOT-regulated employers. This is the first time the DOT is supporting an alternative to urine drug testing.
What does this mean for DOT-regulated and non-DOT regulated employees? Download this document to find out more.
OraSure Technologies empowers the global community to improve health and wellness by providing access to accurate, essential information. Together with its wholly-owned subsidiaries, DNA Genotek, Diversigen, and Novosanis, OraSure provides its customers with end-to-end solutions that encompass tools, services and diagnostics.
The OraSure family of companies is a leader in the development, manufacture, and distribution of rapid diagnostic tests, sample collection and stabilization devices, and molecular services solutions designed to discover and detect critical medical conditions.
OraSure’s portfolio of products is sold globally to clinical laboratories, hospitals, physician’s offices, clinics, public health and community-based organizations, research institutions, government agencies, pharma, commercial entities and direct to consumers.